Evaluation of the relationship between effervescent paracetamol and blood pressure: clinical trial

Mencia Benitez-Camps, Ernest Vinyoles-Bargalló, Oriol Rebagliato-Nadal, Rosa Morros-Pedrós, Helena Pera-Pujadas, Antoni Dalfó-Baqué, Ignacio López-Pavón, Carlos Roca-Sánchez, Rosa Maria Coma-Carbó, Mariano De La Figuera Von Wichmann, Lucas Mengual-Martínez, Carmen Yuste-Marco, Montserrat Teixidó-Colet, Josep M Pepió i Vilaubí, Riera Ciurana-Tost, Rosa Pou-Vila, Ma Antònia Vila-Coll, Josep Maria Bordas-Julve, Rosa Aragonès-Forès, Francisco Javier Pelegrina-Rodríguez, Josep Agudo-Ugena, Carlos Blanco-Mata, Jon de la Iglesia Berrojalbiz, Natalia Burgos-Alonso, Maria Cruz Gómez-Fernández, Mencia Benitez-Camps, Ernest Vinyoles-Bargalló, Oriol Rebagliato-Nadal, Rosa Morros-Pedrós, Helena Pera-Pujadas, Antoni Dalfó-Baqué, Ignacio López-Pavón, Carlos Roca-Sánchez, Rosa Maria Coma-Carbó, Mariano De La Figuera Von Wichmann, Lucas Mengual-Martínez, Carmen Yuste-Marco, Montserrat Teixidó-Colet, Josep M Pepió i Vilaubí, Riera Ciurana-Tost, Rosa Pou-Vila, Ma Antònia Vila-Coll, Josep Maria Bordas-Julve, Rosa Aragonès-Forès, Francisco Javier Pelegrina-Rodríguez, Josep Agudo-Ugena, Carlos Blanco-Mata, Jon de la Iglesia Berrojalbiz, Natalia Burgos-Alonso, Maria Cruz Gómez-Fernández

Abstract

Background: Paracetamol's solubility is achieved by adding to the excipient sodium salts, either as bicarbonate, carbonate or citrate. As the relationship between salt and hypertension is well known, due to the sodium content it has raised a hypothesis that may interfere with the control of that risk factor. Therefore, the objective of this study is to evaluate the effect on blood pressure of effervescent paracetamol compared to non-effervescent, in hypertensive patients.

Methods/design: This is the protocol of a phase IV multicenter clinical trial, randomized, controlled, crossover, open, which will compare the effect of two different formulations of paracetamol (effervescent or non-effervescent) in the blood pressure of hypertensive patients, with a seven weeks follow up. 49 controlled hypertensive patients will be included (clinical BP lower than 150 and 95 mmHg, and lower than 135 mmHg and 85 mmHg in patients with diabetes or a history of cardiovascular event, and daytime ambulatory measurements lower than 140 and 90 mmHg) and mild to moderate pain (Visual Analog Scale between 1 and 4). The study was approved by the ethics committee of the Fundació Jordi Gol i Gurina and following standards of good clinical practice. The primary endpoint will be the variations in systolic BP in 24 h Ambulatory Blood Pressure Monitoring, considering significant differences 2 or more mmHg among those treated with non-effervescent and effervescent formulations. Intention-to-treat and per-protocol analysis will be held.

Discussion: Despite the broad recommendation not to use effervescent drugs in patients with hypertension, there are relatively little studies that show exactly this pressor effect due to sodium in salt that gives the effervescence of the product. This is the first clinical trial designed to study the effect of effervescence compared to the non-effervescent, in well-controlled hypertensive patients with mild to moderate pain, performed in routine clinical practice.

Trial registration: NCT 02514538.

Trial registration: ClinicalTrials.gov NCT02514538.

Figures

Fig. 1
Fig. 1
Flow chart
Fig. 2
Fig. 2
Visit schedule. * If none in the previous 3 months

References

    1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23. doi: 10.1016/S0140-6736(05)70151-3.
    1. Banegas JR. Epidemiología de la hipertensión arterial en España. Situación actual y perspectivas. Hipertensión. 2005;22:353–62. doi: 10.1016/S0212-8241(05)71587-5.
    1. Ezzati M, Hoorn SV, Rodgers A, Lopez AD, Mathers CD, Murray CJ, et al. Estimates of global and regional potential health gains from reducing multiple major risck factors. Lancet. 2003;362:271–80. doi: 10.1016/S0140-6736(03)13968-2.
    1. National Institute for health and clinical Excellence . Osteoarthritis: national clinical guideline for care and management in adults. London: NICE; 2008.
    1. Frishman WH. Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am J Cardiol. 2002;89:18D–25. doi: 10.1016/S0002-9149(02)02233-6.
    1. Chalmers JP, West MJ, Wing LM, Bune AJ, Graham JR. Effects on indomethacin, sulindac, naproxen, aspirin and paracetamol in treated hypertensive patients. Clin Exp Hypertens A. 1984;6:1077–93.
    1. Radack KL, Deck CC, Bloomfield SS. Ibuprofen interferes with the efficacy of antihypertensive drugs. A randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen. Ann Intern Med. 1987;107:628–35. doi: 10.7326/0003-4819-107-5-628.
    1. Forman JP, Rimm EB, Curhan GC. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med. 2007;167:394–9. doi: 10.1001/archinte.167.4.394.
    1. Kurth T, Hennekens CH, Stümer T, Sesso HD, Glynn RJ, Buring JE, et al. Analgesic use and risk of subsequent hypertension in apparently healthy men. Arch Intern Med. 2005;165:1903–9. doi: 10.1001/archinte.165.16.1903.
    1. Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in women. Hypertension. 2005;46:500–7. doi: 10.1161/01.HYP.0000177437.07240.70.
    1. Dedier J, Stampfer MJ, Hankinson SE, Willett WC, Speizer FE, Curhan GC. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension. 2002;40:604–8. doi: 10.1161/01.HYP.0000035856.77718.DA.
    1. Turtle EJ, Dear JW, Webb DJ. A systematic review of the effect of paracetamol on blood pressure in hypertensive and non-hypertensives subjects. BJCP. 2013;75:1396–405.
    1. Dawson J, Fulton R, McInnes GT, Morton R, Morrison D, Padmanabhan S, et al. Acetaminophen use and change in blood pressure in a hypertensive population. J Hypertens. 2013;31:1485–90. doi: 10.1097/HJH.0b013e328360f6f8.
    1. Ubeda A, Llopico J, Sánchez MT. Blood pressure reduction in hypertensive patients after withdrawal of effervescent medication. Pharmacoepidemiol Drug Saf. 2009;18:417–9. doi: 10.1002/pds.1701.
    1. Bendahan Barchilon G, Lizano Díez I, Rodríguez Pérez E, Cortes Pérez PJ, Sorribes Capdevila M, Modamio CP. El sodio como excipiente de los medicamentos podría relacionarse con elevación de la presión arterial en pacientes hipertensos. FAP. 2007;5:90.
    1. Sharma AM, Kribben A, Schattenfroh S, Cetto C, Distler A. Salt sensivity in humans is associated with abnormal acid base regulation. Hypertension. 1990;16:407–13. doi: 10.1161/01.HYP.16.4.407.
    1. Luft FC, Steinberg H, Ganten U, Meyer D, Gless KH, Lang RE, et al. Effect of sodium chloride and sodium bicarbonate on blood pressure in stroke-prone spontaneously hypertensive rats. Clin Sci (Lond) 1988;74:577–85. doi: 10.1042/cs0740577.
    1. Shore AC, Markandu ND, MacGregor GA. A randomized crossover study to compare the blood pressure response to sodium loading with and without chloride in patients with essential hypertension. J Hypertens. 1988;6:613–7. doi: 10.1097/00004872-198808000-00003.
    1. Luft FC, Zemel MB, Sowers JA, Fineberg NS, Weinberger MH. Sodium bicarbonate and sodium chloride: effects on blood pressure and electrolyte homeostasis in normal and hypertensive man. J Hypertens. 1990;8:663–70. doi: 10.1097/00004872-199007000-00010.
    1. Schorr U, Distler A, Sharma AM. Effect of sodium chloride- and sodium bicarbonate-rich mineral water on blood pressure and metabolic parameters in elderly normotensive individuals: a randomized double-blind crossover trial. J Hypertens. 1996;14:131–5.
    1. Sejoong K, Yang JY, Jung ES, Lee J, Heo NJ, Lee JW, et al. Effects of sodium citrate on salt sensitivity and kidney Injury in chronic renal failure. JKMS. 2014;29:1658–64.
    1. O’Brien E, Mee F, Atkins N, O’Malley K. Accuracy of the SpaceLabs 90207 determined by the British Hypertension Society Protocol. J Hypertens. 1991;9(Suppl 5):S25–31.
    1. Ragazzo F, Saladini F, Palatini P. Validation of the Microlife WatchBP 03 device for clinic, home and ambulatory blood pressure measurement, according to the International Protocol. Blood Pressure Monitoring. 2010;15(1):59–62. doi: 10.1097/MBP.0b013e32833531ca.
    1. Parati G, Stergiou G, O’Brien E, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32:1359–66. doi: 10.1097/HJH.0000000000000221.
    1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA. 2003;289:2560–72. doi: 10.1001/jama.289.19.2560.
    1. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J. 2013;34:2159–219. doi: 10.1093/eurheartj/eht151.
    1. Dasgupta K, Quinn RR, Zarnke KB, Rabi DM, Ravani P, Daskalopoulou SS. The 2014 Canadian hypertension education program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2014;30:485–501. doi: 10.1016/j.cjca.2014.02.002.
    1. The clinical management of primary hypertension in adults CG127. .
    1. George J, Majeed W, Mackenzie IS, Macdonald TM, Wei L. Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case–control study. BMJ. 2013;347:f6954. doi: 10.1136/bmj.f6954.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅